NCT00312598 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine Status COMPLETED Phase N/A
NCT00309413 A Clinical Trial on the Antipsychotic Properties of Cannabidiol Status COMPLETED Phase PHASE2
NCT00308360 Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility Status COMPLETED Phase PHASE4
NCT00307216 Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis Status COMPLETED Phase NA
NCT00307203 Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke Status COMPLETED Phase PHASE4
NCT00306475 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Status COMPLETED Phase PHASE4
NCT00305474 Identification and Treatment of the Liability to Develop Schizophrenia Status UNKNOWN Phase PHASE4
NCT00304655 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Status COMPLETED Phase PHASE4
NCT00303602 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Status COMPLETED Phase PHASE4
NCT00302432 The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study Status COMPLETED Phase NA
NCT00300963 Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients Status COMPLETED Phase PHASE2
NCT00300846 A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients Status COMPLETED Phase PHASE4
NCT00300404 Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression Status COMPLETED Phase PHASE3
NCT00299702 Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia Status COMPLETED Phase PHASE4
NCT00297947 High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder Status COMPLETED Phase PHASE2/PHASE3